Patients ages 18 years with active RA with an inadequate response to 1 tumor necrosis factor inhibitor ( TNFi ) and receiving stable background methotrexate were randomized 2:2:1:1 to tofacitinib 5 mg or 10 mg twice daily , or placebo advanced to tofacitinib 5 mg or 10 mg twice daily at month 3 .